Company intelligence / Profile preview

CRAY Innovation

Ownership: Private
Development stage: Other

Overview

CRAY Innovation has developed and patented technology to detect loss of chromosome Y (LOY) in blood cells as a strong predictive biomarker for increased risk of cancer, Alzheimer’s disease, and all-cause mortality in men. The company holds European patents for using LOY as a predictor for both cancer and Alzheimer’s disease. Their ambition is to introduce LOY-tests into clinical genetics practice and further develop the underlying technology.

Therapeutic areas: Men's HealthNeurologyOncologyOther
Modalities: Diagnostic testBiomarker assayGenomic analysis (LOY detection)
Industry: Molecular Diagnostics

Partnerships

Uppsala University Holding AB

Beyond the preview

Go deeper on CRAY Innovation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRAY Innovation.

Explore the full profile